ClinicalTrials.gg
CompletedNCT03261037Updated Mar 26, 2021Results posted

A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

An interventional study of Spirometry and Accelerometry in Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by Hoffmann-La Roche. Completed at 37 sites in 6 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-03-26.

Sponsored by Hoffmann-La Roche · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
178
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-15

Among 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Idiopathic Pulmonary Fibrosis · Hoffmann-La Roche.

Enrollment
11th of 24
178 · median 150
Started
2017
with 2 others
No phase
Only one
of the 29
Registered
26th of 29
by date

Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2017, is the only one with no phase, and was the 26th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

None of the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche is open now. The open studies under Idiopathic Pulmonary Fibrosis, anywhere →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche as a file.
02

Study summary

This international clinical study will enroll participants with a suspected diagnosis of IPF/ILD. This study will characterize the disease behavior of IPF and ILD in the peri-diagnostic period. This objective will be achieved using a multidimensional approach assessing changes in pulmonary function, measured by daily handheld spirometry and site spirometry as well as assessing physical functional capacity at home (accelerometry) and at site (6-minute walk tests [6MWT]). Daily handheld spirometry or physical functional capacity assessments are not routinely performed in this participant population. By following participants' lung function before and after diagnosis using home spirometry, levels of physical activity, as well as self-assessment data from the participants (patient reported outcomes; PRO), the study would provide potentially more rapid information on disease behavior and eventually progression compared to usual clinic measurements that occur only every 3-6 months. By receiving data from daily handheld spirometry measurements, treating physicians may have an improved chance of detecting earlier and outside of hospital visits a decline in lung function that could potentially lead to improvements in both diagnosis and treatment for participants with IPF/ILD.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
  • Interstitial Lung Disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to comply with the study protocol, in the Investigator's judgment - for example, the ability to use the provided spirometer and tablet and the ability to fill in the required patient reported outcomes questionnaires
  • Suspicion of IPF/ILD: radiological evidence of IPF/ILD in symptomatic participants (unexplained dyspnea on exertion and/or cough)

Exclusion criteria

Exclusion Criteria:

  • Participation in any study within 28 days prior to inclusion
  • History of cardiac disease that could explain the patient's symptomatology in the opinion of the Investigator
  • Known history of any connective tissue disease, including, but not limited to, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, or mixed connective tissue disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
178 participants (actual)

Study arms

  • Other
    Participants With Suspicion of IPF/ILD

    A participant will be eligible for inclusion if the Investigator has a suspicion that the participant may have IPF/ILD based on symptoms and radiological evidence.

    Other: Spirometry · Other: Accelerometry · Other: 6MWT

Interventions

  • OtherSpirometry

    Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.

  • OtherAccelerometry

    Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.

  • Other6MWT

    The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.

06

What researchers measure

Primary outcomes

  1. Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home Spirometry

    Minimum site visits were: baseline, diagnosis, and EOS for each participant. From inclusion into the study, participants were followed for up to12 months. The EOS was defined as: If no diagnosis was made 12 months after inclusion, the participant left the study; Participants diagnosed with non-ILD left the study on the date of diagnosis; Participants diagnosed with IPF or non-IPF ILD were followed up to the start of drug treatment (within 6 months) or up to 6 months if no drug treatment was prescribed. Therefore, the total length of the study was variable for each participant. Measurements were taken daily by home spirometry. The semi-annual mean FVC decline was calculated by use of the estimated semi-annual FVC decline of each individual participant. The individual FVC decline was estimated by applying a linear regression model to all acceptable FVC measurements flagged as 'Good blow' collected by the individual participant during the entire peri-diagnostic period (up to 18 months).

    Time frame: From Day 1 into the study to end of the study (up to 18 months) and adjusted for 6 months. There was no fixed visit schedule for the whole study and reported results comprise all data points from enrollment to EOS

Secondary outcomes

  1. Time-Adjusted Semi-Annual FVC Decline in Participants With Non-IPF ILD During the Peri-Diagnostic Period, Measured in mL by Daily Home Spirometry

    Minimum site visits were: baseline, diagnosis, and EOS for each participant. From inclusion into the study, participants were followed for up to12 months. The EOS was defined as: If no diagnosis was made 12 months after inclusion, the participant left the study; Participants diagnosed with non-ILD left the study on the date of diagnosis; Participants diagnosed with IPF or non-IPF ILD were followed up to the start of drug treatment (within 6 months) or up to 6 months if no drug treatment was prescribed. Therefore, the total length of the study was variable for each participant. Measurements were taken daily by home spirometry. The semi-annual mean FVC decline was calculated by use of the estimated semi-annual FVC decline of each individual participant. The individual FVC decline was estimated by applying a linear regression model to all acceptable FVC measurements flagged as 'Good blow' collected by the individual participant during the entire peri-diagnostic period (up to 18 months).

    Time frame: From Day 1 into the study to end of the study (up to 18 months) and adjusted for 6 months. There was no fixed visit schedule for the whole study and reported results comprise all data points from enrollment to EOS

  2. Change From Baseline in the FVC Decline in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured in mL by Site Spirometry

    The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From Baseline to end of the study (up to 18 months)

  3. Change From Baseline in the Percent Predicted FVC in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Site Spirometry

    The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From Baseline to end of the study (up to 18 months)

  4. Change From Baseline in Distance Walked (Meters) on the 6MWT in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Assessed at Site

    The 6MWT measures the distance a patient is able to walk quickly on a flat, hard surface in a period of 6 minutes. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From Baseline to end of the study (up to 18 months)

  5. Decline in Physical Function Capacity (Steps/Day) in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry

    Patients were asked to wear an accelerometer during the course of the study which provided information on their physical activity at home, with daily measurements used to investigate the development of physical function capacity. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  6. Calorie Expenditure in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  7. Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period

    The K-BILD questionnaire was specifically developed to analyze the health status of participants with ILD. The questionnaire consists of 15 items (assessed by the patients on a scale ranging from 1 to 7, where 1 and 7 represent worst and best health status). Items are compiled into 3 domains: breathlessness and activities (range: 0-21), psychological (range: 0-34) , and chest symptoms (range: 0-8). To score the K-BILD, the Likert response scale weightings for individual items are combined and scores are transformed to a range of 0-100 by using logit values (higher scores indicate better health status). The peri-diagnostic period covered the pre-diagnostic period (from enrollment visit participants were followed for up to 12 months) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  8. Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period

    The mMRC dyspnea scale was used to grade the effects of breathlessness on daily activities over time. The following grading categories are used for this scale: Grade 0 - I only get breathless with strenuous exercise; Grade 1 - I get short of breath when hurrying on the level or walking up a slight hill; Grade 2 - I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking on my own pace; Grade 3 - I stop for breath after walking about 100 yards or after a few minutes on level ground; Grade 4 - I am too breathless to leave the house. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  9. The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period

    The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item is rated by the participant on a five-point scale indicating the followings: Level 1 - no problem; Level 2 - slight problems; Level 3 - moderate problems; Level 4 - severe problems; Level 5 - extreme problems. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  10. The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period

    The EQ-VAS questionnaire is a self-reported questionnaire that measures health state. The VAS is a 100 mm scale from worst (0 mm) to best (100 mm) health the participant can imagine. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  11. The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period

    The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A unique health state is defined for each participant by combining the levels from each of the 5 dimensions. Each state is referred to in terms of a 5 digit code, e.g. state 11111 indicates no problems on any of the 5 dimensions, while state 12345 indicates no problems with mobility, slight problems with washing or dressing, moderate problems with usual activities, severe pain or discomfort and extreme anxiety or depression. From these 5 answers an index value is derived between 0 and 1, with a higher value corresponding with a better Quality of Life.

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  12. Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period

    The FAS is a fatigue questionnaire consisting of 10 items; five questions reflect physical fatigue and five questions analyze mental fatigue. A five-point scale (one for "never" to five for "always") is used for participant responses. The scale score is calculated by summing all items. Therefore, the FAS scores can range from 10 to 50. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  13. Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period

    The VAS are 100 mm scales on which participants indicate the severity of their cough, the urge to cough and their fatigue. In the VAS, participants had to record their health state on a scale ranging from 0 (best imaginable health state) to 100 (worst imaginable health state). A mean of this health state was recorded for participant analyzed in this outcome measure. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  14. Pearson's Correlation Coefficient of FVC (mL) Between Home and Site Spirometry in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period

    The correlation of FVC (mL) between home and site spirometry was analyzed by taking into account the individually estimated linear regression models of each participant for home-based FVC measurements and site FVC measurements. This analysis was performed for participants diagnosed with IPF or non-IPF ILD in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  15. Pearson's Correlation Coefficient of Physical Functional Capacity Assessed at Home in Terms of the Decline in the Number of Footsteps and on Site in Terms of the Decline in Distance of the 6MWT

    The measure represents the correlation of distance walked (meter) assessed by physical function capacity at home and the 6MWT at the site in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  16. Percentage of Participants Requiring Respiratory-Related Hospitalizations

    The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period.

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  17. Percentage of Participants With Non-Elective Hospitalizations

    The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  18. Percentage of Participants With Investigator-Reported Acute Exacerbations

    Acute exacerbation was defined as per Collard et al. 2016. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  19. Percentage of Participants Who Died Due to Any Cause

    The number of participants, who died due to any cause, were counted during pre- and post-diagnosis period.

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  20. Percentage of Participants Who Died Due to Respiratory-Related Diseases

    The number of participants, who died due to respiratory-related diseases, were counted during pre- and post-diagnosis period.

    Time frame: From inclusion into the study to end of the study (up to 18 months)

  21. Percentage of Participants With Events Related to the Study Assessments

    The number of participants with events related to the study assessments were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.

    Time frame: From inclusion into the study to end of the study (up to 18 months)

07

Results

Posted Mar 26, 2021

Participant flow

The study enrolled participants in Canada, France, Ireland, Italy, the Netherlands, and Russia.

Participant flow — Overall Study
MilestoneIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
Started6862939
Completed6441911
Not completed421028
Withdrew: Withdrawal by subject213018
Withdrew: Non-compliance with study procedures0206
Withdrew: Participant moving away and can no longer be in study0100
Withdrew: Participant came out of study due to investigator discretion0200
Withdrew: Diagnosed but protocol deviation1000
Withdrew: Participant did not want to continue the study0100
Withdrew: Participant did not want to continue the diagnostic procedures0001
Withdrew: Participant presented clinical improvement0200
Withdrew: Technical difficulties0001
Withdrew: Equipment failed to work0001
Withdrew: End of study for participant and no follow up0001
Withdrew: Participant was too weak to continue in study1000

Outcome measures

PrimaryTime-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home Spirometry

Minimum site visits were: baseline, diagnosis, and EOS for each participant. From inclusion into the study, participants were followed for up to12 months. The EOS was defined as: If no diagnosis was made 12 months after inclusion, the participant left the study; Participants diagnosed with non-ILD left the study on the date of diagnosis; Participants diagnosed with IPF or non-IPF ILD were followed up to the start of drug treatment (within 6 months) or up to 6 months if no drug treatment was prescribed. Therefore, the total length of the study was variable for each participant. Measurements were taken daily by home spirometry. The semi-annual mean FVC decline was calculated by use of the estimated semi-annual FVC decline of each individual participant. The individual FVC decline was estimated by applying a linear regression model to all acceptable FVC measurements flagged as 'Good blow' collected by the individual participant during the entire peri-diagnostic period (up to 18 months).

Time frame:
From Day 1 into the study to end of the study (up to 18 months) and adjusted for 6 months. There was no fixed visit schedule for the whole study and reported results comprise all data points from enrollment to EOS
Reported as:
Mean · milliliter (mL)
Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home Spirometry
milliliter (mL)IPF Participants
Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home Spirometry-308.7 ± 1268.72
SecondaryTime-Adjusted Semi-Annual FVC Decline in Participants With Non-IPF ILD During the Peri-Diagnostic Period, Measured in mL by Daily Home Spirometry

Minimum site visits were: baseline, diagnosis, and EOS for each participant. From inclusion into the study, participants were followed for up to12 months. The EOS was defined as: If no diagnosis was made 12 months after inclusion, the participant left the study; Participants diagnosed with non-ILD left the study on the date of diagnosis; Participants diagnosed with IPF or non-IPF ILD were followed up to the start of drug treatment (within 6 months) or up to 6 months if no drug treatment was prescribed. Therefore, the total length of the study was variable for each participant. Measurements were taken daily by home spirometry. The semi-annual mean FVC decline was calculated by use of the estimated semi-annual FVC decline of each individual participant. The individual FVC decline was estimated by applying a linear regression model to all acceptable FVC measurements flagged as 'Good blow' collected by the individual participant during the entire peri-diagnostic period (up to 18 months).

Time frame:
From Day 1 into the study to end of the study (up to 18 months) and adjusted for 6 months. There was no fixed visit schedule for the whole study and reported results comprise all data points from enrollment to EOS
Reported as:
Mean · mL
Time-Adjusted Semi-Annual FVC Decline in Participants With Non-IPF ILD During the Peri-Diagnostic Period, Measured in mL by Daily Home Spirometry
mLNon-IPF ILD Participants
Time-Adjusted Semi-Annual FVC Decline in Participants With Non-IPF ILD During the Peri-Diagnostic Period, Measured in mL by Daily Home Spirometry57.5 ± 1277.03
SecondaryChange From Baseline in the FVC Decline in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured in mL by Site Spirometry

The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From Baseline to end of the study (up to 18 months)
Reported as:
Mean · mL
Change From Baseline in the FVC Decline in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured in mL by Site Spirometry
mLIPF ParticipantsNon-IPF ILD Participants
Baseline2845.6 ± 814.832782.4 ± 870.24
Change from Baseline at End of Study Visit-51.3 ± 270.56-27.1 ± 265.52
SecondaryChange From Baseline in the Percent Predicted FVC in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Site Spirometry

The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From Baseline to end of the study (up to 18 months)
Reported as:
Mean · Percent Predicted (%)
Change From Baseline in the Percent Predicted FVC in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Site Spirometry
Percent Predicted (%)IPF ParticipantsNon-IPF ILD Participants
Baseline82.8 ± 18.7483.9 ± 17.82
Change form Baseline at End of Study Visit-0.6 ± 7.26-0.6 ± 8.49
SecondaryChange From Baseline in Distance Walked (Meters) on the 6MWT in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Assessed at Site

The 6MWT measures the distance a patient is able to walk quickly on a flat, hard surface in a period of 6 minutes. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From Baseline to end of the study (up to 18 months)
Reported as:
Mean · Meter (m)
Change From Baseline in Distance Walked (Meters) on the 6MWT in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Assessed at Site
Meter (m)IPF ParticipantsNon-IPF ILD Participants
Baseline434.6 ± 117.30429.4 ± 139.51
Change from Baseline at End of Study Visit4.4 ± 96.186.4 ± 87.97
SecondaryDecline in Physical Function Capacity (Steps/Day) in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry

Patients were asked to wear an accelerometer during the course of the study which provided information on their physical activity at home, with daily measurements used to investigate the development of physical function capacity. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Mean · Steps per Day
Decline in Physical Function Capacity (Steps/Day) in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry
Steps per DayIPF ParticipantsNon-IPF ILD Participants
Decline in Physical Function Capacity (Steps/Day) in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry-1237.2 ± 14146.07-13407.3 ± 72612.82
SecondaryCalorie Expenditure in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry
Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Number · Calorie
Calorie Expenditure in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry
CalorieIPF ParticipantsNon-IPF ILD Participants
Calorie Expenditure in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home AccelerometryNANA
SecondaryChange in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period

The K-BILD questionnaire was specifically developed to analyze the health status of participants with ILD. The questionnaire consists of 15 items (assessed by the patients on a scale ranging from 1 to 7, where 1 and 7 represent worst and best health status). Items are compiled into 3 domains: breathlessness and activities (range: 0-21), psychological (range: 0-34) , and chest symptoms (range: 0-8). To score the K-BILD, the Likert response scale weightings for individual items are combined and scores are transformed to a range of 0-100 by using logit values (higher scores indicate better health status). The peri-diagnostic period covered the pre-diagnostic period (from enrollment visit participants were followed for up to 12 months) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Mean · Units on scale
Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period
Units on scaleIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
Baseline60.57 ± 17.63355.70 ± 14.20354.22 ± 11.70360.47 ± 15.728
Change from Baseline at End of Study Visit-0.45 ± 9.7093.98 ± 11.8516.03 ± 14.2944.01 ± 9.313
SecondaryModified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period

The mMRC dyspnea scale was used to grade the effects of breathlessness on daily activities over time. The following grading categories are used for this scale: Grade 0 - I only get breathless with strenuous exercise; Grade 1 - I get short of breath when hurrying on the level or walking up a slight hill; Grade 2 - I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking on my own pace; Grade 3 - I stop for breath after walking about 100 yards or after a few minutes on level ground; Grade 4 - I am too breathless to leave the house. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Count of participants · Participants
Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period
ParticipantsIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
Pre-diagnosis — Grade 0121026
Pre-diagnosis — Grade 188111
Pre-diagnosis — Grade 27932
Pre-diagnosis — Grade 33211
Pre-diagnosis — Grade 40000
Initial diagnosis — Grade 0221732
Initial diagnosis — Grade 1312500
Initial diagnosis — Grade 2101631
Initial diagnosis — Grade 35320
Initial diagnosis — Grade 40000
Post-diagnosis — Grade 021——
Post-diagnosis — Grade 142——
Post-diagnosis — Grade 200——
Post-diagnosis — Grade 300——
Post-diagnosis — Grade 400——
End of Study — Grade 02017313
End of Study — Grade 13025115
End of Study — Grade 2101633
End of Study — Grade 35321
End of Study — Grade 40000
SecondaryThe EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period

The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item is rated by the participant on a five-point scale indicating the followings: Level 1 - no problem; Level 2 - slight problems; Level 3 - moderate problems; Level 4 - severe problems; Level 5 - extreme problems. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Count of participants · Participants
The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period
ParticipantsIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
Baseline Mobility — Level 13325224
Baseline Mobility — Level 2161529
Baseline Mobility — Level 3142154
Baseline Mobility — Level 45101
Baseline Mobility — Level 50000
Baseline Mobility — Missing0000
Baseline Self-care — Level 15552634
Baseline Self-care — Level 27624
Baseline Self-care — Level 36410
Baseline Self-care — Level 40000
Baseline Self-care — Level 50000
Baseline Self-care — Missing0000
Baseline Usual activities — Level 13229420
Baseline Usual activities — Level 21916210
Baseline Usual activities — Level 3161524
Baseline Usual activities — Level 41204
Baseline Usual activities — Level 50010
Baseline Usual activities — Missing0000
Baseline Pain/Discomfort — Level 12925320
Baseline Pain/Discomfort — Level 22222210
Baseline Pain/Discomfort — Level 3171434
Baseline Pain/Discomfort — Level 40113
Baseline Pain/Discomfort — Level 50001
Baseline Pain/Discomfort — Missing0000
Baseline Anxiety/Depression — Level 13824519
Baseline Anxiety/Depression — Level 22220212
Baseline Anxiety/Depression — Level 351527
Baseline Anxiety/Depression — Level 42200
Baseline Anxiety/Depression — Level 51100
Baseline Anxiety/Depression — Missing0000
Pre-diagnosis Mobility — Level 11611113
Pre-diagnosis Mobility — Level 24924
Pre-diagnosis Mobility — Level 39521
Pre-diagnosis Mobility — Level 41322
Pre-diagnosis Mobility — Level 50000
Pre-diagnosis Mobility — Missing0101
Pre-diagnosis Self-care — Level 12525520
Pre-diagnosis Self-care — Level 23220
Pre-diagnosis Self-care — Level 31100
Pre-diagnosis Self-care — Level 41000
Pre-diagnosis Self-care — Level 50000
Pre-diagnosis Self-care — Missing0101
Pre-diagnosis Usual activities — Level 1151529
Pre-diagnosis Usual activities — Level 210636
Pre-diagnosis Usual activities — Level 34724
Pre-diagnosis Usual activities — Level 41000
Pre-diagnosis Usual activities — Level 50001
Pre-diagnosis Usual activities — Missing0101
Pre-diagnosis Pain/Discomfort — Level 11515112
Pre-diagnosis Pain/Discomfort — Level 211743
Pre-diagnosis Pain/Discomfort — Level 33504
Pre-diagnosis Pain/Discomfort — Level 41120
Pre-diagnosis Pain/Discomfort — Level 50001
Pre-diagnosis Pain/Discomfort — Missing0101
Pre-diagnosis Anxiety/Depression — Level 11412210
Pre-diagnosis Anxiety/Depression — Level 2111048
Pre-diagnosis Anxiety/Depression — Level 33611
Pre-diagnosis Anxiety/Depression — Level 40000
Pre-diagnosis Anxiety/Depression — Level 52001
Pre-diagnosis Anxiety/Depression — Missing0101
Initial diagnosis Mobility — Level 1312622
Initial diagnosis Mobility — Level 2191730
Initial diagnosis Mobility — Level 312920
Initial diagnosis Mobility — Level 43610
Initial diagnosis Mobility — Level 50000
Initial diagnosis Mobility — Missing3401
Initial diagnosis Self-care — Level 1554462
Initial diagnosis Self-care — Level 231010
Initial diagnosis Self-care — Level 36410
Initial diagnosis Self-care — Level 41000
Initial diagnosis Self-care — Level 50000
Initial diagnosis Self-care — Missing3401
Initial diagnosis Usual activities — Level 1312762
Initial diagnosis Usual activities — Level 2201410
Initial diagnosis Usual activities — Level 391410
Initial diagnosis Usual activities — Level 44300
Initial diagnosis Usual activities — Level 51000
Initial diagnosis Usual activities — Missing3401
Initial diagnosis Pain/Discomfort — Level 1323421
Initial diagnosis Pain/Discomfort — Level 2221411
Initial diagnosis Pain/Discomfort — Level 310630
Initial diagnosis Pain/Discomfort — Level 41420
Initial diagnosis Pain/Discomfort — Level 50000
Initial diagnosis Pain/Discomfort — Missing3401
Initial diagnosis Anxiety/Depression — Level 1302541
Initial diagnosis Anxiety/Depression — Level 2211711
Initial diagnosis Anxiety/Depression — Level 3101310
Initial diagnosis Anxiety/Depression — Level 42320
Initial diagnosis Anxiety/Depression — Level 52000
Initial diagnosis Anxiety/Depression — Missing3401
Post-diagnosis Mobility — Level 120——
Post-diagnosis Mobility — Level 212——
Post-diagnosis Mobility — Level 321——
Post-diagnosis Mobility — Level 400——
Post-diagnosis Mobility — Level 500——
Post-diagnosis Mobility — Missing10——
Post-diagnosis Self-care — Level 142——
Post-diagnosis Self-care — Level 201——
Post-diagnosis Self-care — Level 310——
Post-diagnosis Self-care — Level 400——
Post-diagnosis Self-care — Level 500——
Post-diagnosis Self-care — Missing10——
Post-diagnosis Usual activities — Level 122——
Post-diagnosis Usual activities — Level 220——
Post-diagnosis Usual activities — Level 311——
Post-diagnosis Usual activities — Level 400——
Post-diagnosis Usual activities — Level 500——
Post-diagnosis Usual activities — Missing10——
Post-diagnosis Pain/Discomfort — Level 112——
Post-diagnosis Pain/Discomfort — Level 240——
Post-diagnosis Pain/Discomfort — Level 301——
Post-diagnosis Pain/Discomfort — Level 400——
Post-diagnosis Pain/Discomfort — Level 500——
Post-diagnosis Pain/Discomfort — Missing10——
Post-diagnosis Anxiety/Depression — Level 130——
Post-diagnosis Anxiety/Depression — Level 212——
Post-diagnosis Anxiety/Depression — Level 311——
Post-diagnosis Anxiety/Depression — Level 400——
Post-diagnosis Anxiety/Depression — Level 500——
Post-diagnosis Anxiety/Depression — Missing10——
End of Study Mobility — Level 13328216
End of Study Mobility — Level 2151532
End of Study Mobility — Level 3111434
End of Study Mobility — Level 44312
End of Study Mobility — Level 50000
End of Study Mobility — Missing2209
End of Study Self-care — Level 15446622
End of Study Self-care — Level 231221
End of Study Self-care — Level 35211
End of Study Self-care — Level 41000
End of Study Self-care — Level 50000
End of Study Self-care — Missing2209
End of Study Usual activities — Level 13225414
End of Study Usual activities — Level 2161805
End of Study Usual activities — Level 3111544
End of Study Usual activities — Level 43211
End of Study Usual activities — Level 51000
End of Study Usual activities — Missing2209
End of Study Pain/Discomfort — Level 13034214
End of Study Pain/Discomfort — Level 2201613
End of Study Pain/Discomfort — Level 313846
End of Study Pain/Discomfort — Level 40221
End of Study Pain/Discomfort — Level 50000
End of Study Pain/Discomfort — Missing2209
End of Study Anxiety/Depression — Level 12825413
End of Study Anxiety/Depression — Level 22119110
End of Study Anxiety/Depression — Level 3101520
End of Study Anxiety/Depression — Level 42121
End of Study Anxiety/Depression — Level 52000
End of Study Anxiety/Depression — Missing2209
SecondaryThe EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period

The EQ-VAS questionnaire is a self-reported questionnaire that measures health state. The VAS is a 100 mm scale from worst (0 mm) to best (100 mm) health the participant can imagine. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Mean · Scores on a scale
The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period
Scores on a scaleIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
Health State Index Baseline71.7 ± 15.9667.4 ± 20.1168.9 ± 17.9976.2 ± 17.09
Health State Index Pre-diagnosis69.8 ± 15.5071.5 ± 15.8965.7 ± 19.8873.5 ± 16.06
Health State Index Initial diagnosis69.5 ± 16.2368.3 ± 18.0370.4 ± 19.9272.5 ± 10.61
Health State Index Post-diagnosis69.0 ± 25.1076.7 ± 12.58——
Health State Index End of Study69.5 ± 16.4669.8 ± 17.2167.0 ± 21.2174.2 ± 16.85
SecondaryThe EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period

The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A unique health state is defined for each participant by combining the levels from each of the 5 dimensions. Each state is referred to in terms of a 5 digit code, e.g. state 11111 indicates no problems on any of the 5 dimensions, while state 12345 indicates no problems with mobility, slight problems with washing or dressing, moderate problems with usual activities, severe pain or discomfort and extreme anxiety or depression. From these 5 answers an index value is derived between 0 and 1, with a higher value corresponding with a better Quality of Life.

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Mean · Scores on a scale
The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period
Scores on a scaleIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
Index utility score Baseline0.83 ± 0.1400.79 ± 0.1430.67 ± 0.2500.80 ± 0.187
Index utility score Pre-diagnosis0.82 ± 0.1540.80 ± 0.1520.68 ± 0.2370.83 ± 0.182
Index utility score Initial diagnosis0.81 ± 0.1620.78 ± 0.1970.63 ± 0.3310.92 ± 0.013
Index utility score Post-diagnosis0.81 ± 0.1490.75 ± 0.123——
Index utility score End of Study0.81 ± 0.1640.80 ± 0.1640.62 ± 0.3120.81 ± 0.197
SecondaryFatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period

The FAS is a fatigue questionnaire consisting of 10 items; five questions reflect physical fatigue and five questions analyze mental fatigue. A five-point scale (one for "never" to five for "always") is used for participant responses. The scale score is calculated by summing all items. Therefore, the FAS scores can range from 10 to 50. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Mean · Scores on a Scale
Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period
Scores on a ScaleIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
Baseline21.8 ± 6.4421.8 ± 6.8921.1 ± 7.2220.9 ± 6.99
Initial diagnosis21.7 ± 6.6622.6 ± 7.3324.7 ± 9.1118.0 ± 2.83
End of study22.0 ± 6.1722.0 ± 7.5926.1 ± 9.3320.6 ± 6.31
SecondaryCough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period

The VAS are 100 mm scales on which participants indicate the severity of their cough, the urge to cough and their fatigue. In the VAS, participants had to record their health state on a scale ranging from 0 (best imaginable health state) to 100 (worst imaginable health state). A mean of this health state was recorded for participant analyzed in this outcome measure. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Mean · Scores on a Scale
Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period
Scores on a ScaleIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
Baseline (Cough)34.0 ± 25.4426.9 ± 20.6617.9 ± 21.9927.4 ± 20.38
Pre-diagnosis (Cough)36.8 ± 25.5025.4 ± 20.9011.4 ± 14.0331.4 ± 24.34
Initial diagnosis (Cough)36.3 ± 29.6021.9 ± 18.8817.1 ± 21.6932.0 ± 36.77
Post-diagnosis (Cough)25.6 ± 20.9417.0 ± 9.16——
End of Study (Cough)34.7 ± 26.6424.0 ± 19.4219.3 ± 21.3531.2 ± 25.92
Baseline (Urge to Cough)33.3 ± 25.4128.6 ± 21.5316.4 ± 17.2025.8 ± 21.27
Pre-diagnosis (Urge to Cough)37.6 ± 25.7323.1 ± 20.0313.2 ± 13.5130.4 ± 24.29
Initial diagnosis (Urge to Cough)36.4 ± 29.2222.9 ± 19.0213.7 ± 19.8638.5 ± 47.38
Post-diagnosis (Urge to Cough)23.5 ± 15.7910.8 ± 9.00——
End of Study (Urge to Cough)33.8 ± 25.1824.3 ± 20.1416.2 ± 20.0036.3 ± 29.75
Baseline (Fatigue)38.4 ± 27.1539.4 ± 24.2930.0 ± 31.1833.2 ± 26.89
Pre-diagnosis (Fatigue)34.1 ± 27.5031.0 ± 22.6832.5 ± 26.1132.0 ± 28.29
Initial diagnosis (Fatigue)37.5 ± 27.5035.6 ± 23.7931.1 ± 30.0017.0 ± 5.66
Post-diagnosis (Fatigue)30.4 ± 23.2425.3 ± 19.48——
End of Study (Fatigue)38.3 ± 26.1534.6 ± 23.5435.5 ± 32.1631.5 ± 24.18
SecondaryPearson's Correlation Coefficient of FVC (mL) Between Home and Site Spirometry in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period

The correlation of FVC (mL) between home and site spirometry was analyzed by taking into account the individually estimated linear regression models of each participant for home-based FVC measurements and site FVC measurements. This analysis was performed for participants diagnosed with IPF or non-IPF ILD in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Number · Pearson's Correlation Coefficients
Pearson's Correlation Coefficient of FVC (mL) Between Home and Site Spirometry in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period
Pearson's Correlation CoefficientsIPF ParticipantsNon-IPF ILD Participants
Pearson's Correlation Coefficient of FVC (mL) Between Home and Site Spirometry in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period-0.060.35
SecondaryPearson's Correlation Coefficient of Physical Functional Capacity Assessed at Home in Terms of the Decline in the Number of Footsteps and on Site in Terms of the Decline in Distance of the 6MWT

The measure represents the correlation of distance walked (meter) assessed by physical function capacity at home and the 6MWT at the site in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Number · Pearson's Correlation Coefficients
Pearson's Correlation Coefficient of Physical Functional Capacity Assessed at Home in Terms of the Decline in the Number of Footsteps and on Site in Terms of the Decline in Distance of the 6MWT
Pearson's Correlation CoefficientsIPF ParticipantsNon-IPF ILD Participants
Pearson's Correlation Coefficient of Physical Functional Capacity Assessed at Home in Terms of the Decline in the Number of Footsteps and on Site in Terms of the Decline in Distance of the 6MWT-0.040.06
SecondaryPercentage of Participants Requiring Respiratory-Related Hospitalizations

The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period.

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants Requiring Respiratory-Related Hospitalizations
Percentage of ParticipantsIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
With at least one event during pre-diagnosis period5.94.822.22.6
With at least one event during post-diagnosis period0000
SecondaryPercentage of Participants With Non-Elective Hospitalizations

The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Non-Elective Hospitalizations
Percentage of ParticipantsIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
With at least one event during pre-diagnosis period8.84.822.27.7
With at least one event during post-diagnosis period2.9000
SecondaryPercentage of Participants With Investigator-Reported Acute Exacerbations

Acute exacerbation was defined as per Collard et al. 2016. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Investigator-Reported Acute Exacerbations
Percentage of ParticipantsIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
With at least one acute exacerbation pre-diagnosis period1.5000
With at least one acute exacerbation during post-diagnosis period00——
With at least one triggered acute exacerbation pre-diagnosis period4.4000
With at least one triggered acute exacerbation during post-diagnosis period00——
With at least one idiopathic acute exacerbation pre-diagnosis period01.600
With at least one idiopathic acute exacerbation during post-diagnosis period00——
SecondaryPercentage of Participants Who Died Due to Any Cause

The number of participants, who died due to any cause, were counted during pre- and post-diagnosis period.

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Died Due to Any Cause
Percentage of ParticipantsIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
Percentage of Participants Who Died Due to Any Cause0000
SecondaryPercentage of Participants Who Died Due to Respiratory-Related Diseases

The number of participants, who died due to respiratory-related diseases, were counted during pre- and post-diagnosis period.

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Died Due to Respiratory-Related Diseases
Percentage of ParticipantsIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
Percentage of Participants Who Died Due to Respiratory-Related Diseases0000
SecondaryPercentage of Participants With Events Related to the Study Assessments

The number of participants with events related to the study assessments were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.

Time frame:
From inclusion into the study to end of the study (up to 18 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Events Related to the Study Assessments
Percentage of ParticipantsIPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without Diagnosis
Percentage of Participants With Events Related to the Study Assessments03.205.1

Adverse events

Collected over From inclusion into the study to end of the study (up to 18 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IPF Participants0/68 (0%)——
Participants With and an ILD Other Than IPF (Non-IPF ILD)0/62 (0%)——
Non-ILD Participants0/9 (0%)——
Participants Without Diagnosis0/39 (0%)——

Baseline characteristics

Age, Continuous
Age, Continuous(Years)IPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without DiagnosisTotal
Mean69.3 ± 6.9765.1 ± 9.9969.6 ± 7.771.2 ± 8.6468.3 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)IPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without DiagnosisTotal
Female193231266
Male4930627112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without DiagnosisTotal
American Indian or Alaskan Native10001
White6250724143
Unknown01001
Missing51121533
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participant)IPF ParticipantsNon-IPF ILD ParticipantsNon-ILD ParticipantsParticipants Without DiagnosisTotal
Hispanic or Latino9120122
Not Hispanic or Latin4936720112
Not reported43029
Unknown10012
Missing51121533
08

Study locations

37 sites
  • St. Clare'S Mercy Hospital
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Kingston Health Sciences Centre; research Kingston General Health Research Institute
    Kingston, Ontario K7L 5G2, Canada
  • Dr. Syed Anees Medicine Profession Corporation
    Windsor, Ontario N8X 1T3, Canada
  • Clinique de pneumologie et du sommeil de Lanaudiere
    Saint-Charles-Borromee, Quebec J6E 2B4, Canada
  • Hopital Louis Pradel; Pneumologie
    Bron, 69677, France
  • Hopital Cote De Nacre; Pneumologie
    Caen, 14000, France
  • Ch De Granville; Pneumologie
    Granville, 50406, France
  • Hopital Calmette; Pneumologie
    Lille, 59037, France
  • Hopital Arnaud De Villeneuve; Pneumologie A
    Montpellier, 34295, France
  • Hopital Tenon;Pneumologie
    Paris, 75970, France
  • Centre Pneumologie Et Allergie
    Perpignan, 66025, France
  • Hopital de Pontchaillou; Service de Pneumologie
    Rennes, 35033, France
  • Ch Bretagne Atlantique; Pneumologie-Oncologie
    Vannes, 56017, France
  • Cork University Hospital
    Cork, Ireland
  • St James's Hospital
    Dublin, 8, Ireland
  • P.O. Clinicizz. 'SS. Annunziata'; U.O.C. Pneumologia
    Chieti, Abruzzo 66100, Italy
  • Azienda Ospedaliera dei Colli - P. Monaldi; Dip. Medicina Clinica e Chirurgia
    Napoli, Campania 80131, Italy
  • A.O. Universitaria Policlinico Di Modena; DIP. Malattie Dell'apparato Respiratorio
    Modena, Emilia-Romagna 41124, Italy
  • Policlinico A. Gemelli e C.I.C.; Polo Scienze Cardiovascolari e Toraciche - UOC Pneumologia
    Roma, Lazio 00168, Italy
  • Az. Osp.Univ.San Martino; Pneumologia
    Genova, Liguria 16132, Italy
  • ASST Rhodense; U.O.C. Pneumologia
    Garbagnate Milanese (MI), Lombardia 20024, Italy
  • Ospedale Policlinico S. Matteo; S.C. Pneumologia
    Pavia, Lombardia 27100, Italy
  • Pres. Osp. Unico ZT9 - Ospedale Generale Provinciale; U.O.C. Pneumologia
    Macerata, Marche 62100, Italy
  • A.O.U. S. Luigi Gonzaga; Interstiziopatie Malattie Rare Polmone
    Orbassano (to), Piemonte 10043, Italy
  • A.O.U. Sassari; Dip. Medicina Clinica e Sperimentale
    Sassari, Sardegna 07100, Italy
  • Az. Osp. Univ. P. Giaccone; UOC di Pneumologia
    Palermo, Sicilia 90127, Italy
  • Azienda Ospedaliero-Universitaria Careggi; SOD Pneumologia e Fisiopatologia Toracico Polmonare
    Firenze, Toscana 50134, Italy
  • Admiraal de Ruijter Ziekenhuis
    Goes, 4462 RA, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3000 CA, Netherlands
  • Isala
    Zwolle, 8025 AB, Netherlands
  • SBEI HPE "The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova"of MoH of RF
    Sankt-peterburg, Leningrad 197022, Russian Federation
  • Pulmonologii NII FMBA of Russia
    Moscow, Moskovskaja Oblast, Russian Federation
  • SBI at Rostov Region "Regional Clinical Hospital #2"
    Rostov-na-donu, Rostov 344029, Russian Federation
  • SBIH "Chelyabinsk Regional Clinical Hospital"
    Chelyabinsk, Sverdlovsk 454076, Russian Federation
  • Municipal Healthcare Institution City Clinical Hospital #3 named after M.A. Podgorbunskogo
    Kemerovo, 650099, Russian Federation
  • SBIH at Vladimir Region "Regional Clinical Hospital"
    Vladimir, 600023, Russian Federation
  • Budget Institution of Healthcare of Voronezh Region "Voronezh Regional Clinical Hospital #1"
    Voronezh, 394066, Russian Federation
09

References and documents

Publications

  • Wijsenbeek MS, Bendstrup E, Valenzuela C, Henry MT, Moor CC, Jouneau S, Fois AG, Moran-Mendoza O, Anees S, Mirt M, Bengus M, Gilberg F, Kirchgaessler KU, Vancheri C. Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. Adv Ther. 2021 Jul;38(7):4040-4056. doi: 10.1007/s12325-021-01790-y. Epub 2021 Jun 11. PubMed 34117601 ↗
  • Wijsenbeek M, Bendstrup E, Valenzuela C, Henry MT, Moor C, Bengus M, Perjesi A, Gilberg F, Kirchgaessler KU, Vancheri C. Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. Adv Ther. 2019 Jan;36(1):232-243. doi: 10.1007/s12325-018-0845-3. Epub 2018 Nov 30. PubMed 30506309 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Nov 2019, 23 months.

Results were first posted in Mar 2021, 1 year 3 months after primary completion.

Of 52 interventional studies with no phase under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 53. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2017
First posted
Aug 24, 2017
StartActual
Dec 25, 2017
Primary completionActual
Nov 27, 2019
CompletionActual
Nov 27, 2019
Results first posted
Mar 26, 2021
Last update
Mar 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03261037
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 24, 2017
Start date
Dec 25, 2017
Primary completion
Nov 27, 2019
Completion
Nov 27, 2019
Results posted
Mar 26, 2021
Last update
Mar 26, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion